Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.2
Journals
Microorganisms
Special Issues
New Strategies for Antimicrobial Treatment
share announcement

New Strategies for Antimicrobial Treatment

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Antimicrobial Agents and Resistance".

Deadline for manuscript submissions: 31 March 2026 | Viewed by 2501

Special Issue Editor

Dr. Chen Fu

E-Mail Website
Guest Editor
College of Pharmaceutical Sciences, Southwest University, Chongqing, China
Interests: metal-based novel antimicrobial agents and their targeted therapy

Special Issue Information

Dear Colleagues,

This Special Issue is dedicated to advancing the field of antimicrobial treatments by highlighting innovative strategies to counteract antimicrobial resistance. It aims to consolidate groundbreaking research on new antimicrobial agents, their unique mechanisms, and environmental implications. The Issue actively promotes interdisciplinary collaboration among microbiologists, pharmacologists, molecular biologists, and clinicians to hasten the transition of research findings into clinical applications. It seeks to widely disseminate cutting-edge findings to refine existing treatments and inspire the creation of novel therapeutic options. Contributions are invited on alternative therapies, resistance mechanisms, and combination therapies that enhance efficacy and minimize resistance development. The inclusion of diverse clinical trials and case studies will offer valuable insights into treatment effectiveness. Additionally, the Issue will emphasize the importance of pharmacokinetic and pharmacodynamic studies for personalized medicine and robust preclinical research to support clinical trials.

Dr. Chen Fu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial treatments
  • antimicrobial resistance
  • innovative strategies
  • new antimicrobial agents
  • clinical applications
  • alternative therapies
  • resistance mechanisms
  • combination therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 3143 KB  
Article
Fisetin as an Antiviral Agent Targeting the RNA-Dependent RNA Polymerase of SARS-CoV-2: Computational Prediction and In Vitro Experimental Validation
by Ximena Hernández-Rodríguez, Flor Itzel Lira-Hernández, José Manuel Reyes-Ruíz, Juan Fidel Osuna-Ramos, Carlos Noe Farfán-Morales, Daniela Nahomi Calderón-Sandate, Julio Enrique Castañeda-Delgado, Moisés León-Juárez, Rosa María del Ángel, Bruno Rivas-Santiago, Saúl Noriega, David Mauricio Cañedo-Figueroa, Sarita Montaño, Alan Orlando Santos-Mena, Ana Cristina García-Herrera and Luis Adrián De Jesús-González
Microorganisms 2025, 13(12), 2809; https://doi.org/10.3390/microorganisms13122809 - 10 Dec 2025
Viewed by 29
Abstract
SARS-CoV-2 continues to evolve into immune-evasive variants, and although vaccination remains the cornerstone of prevention, the search for antiviral molecules targeting conserved viral enzymes remains essential. The RNA-dependent RNA polymerase (NSP12) is a central component of coronavirus replication, and natural polyphenols have been [...] Read more.
SARS-CoV-2 continues to evolve into immune-evasive variants, and although vaccination remains the cornerstone of prevention, the search for antiviral molecules targeting conserved viral enzymes remains essential. The RNA-dependent RNA polymerase (NSP12) is a central component of coronavirus replication, and natural polyphenols have been recurrently proposed as modulators of viral polymerases. Among these compounds, Fisetin has been reported to interact with multiple viral and cellular pathways, yet its direct antiviral activity against SARS-CoV-2 remained largely unexplored. Here, we first analyzed the interaction of Fisetin with the catalytic and NiRAN domains of NSP12 using molecular docking and molecular dynamics simulations, revealing stable and energetically favorable binding throughout a 100 ns simulation. Previous biochemical reports have shown that Fisetin inhibits the recombinant SARS-CoV-2 RdRp, supporting its potential to engage the polymerase. We then evaluated its antiviral activity in human A549 lung epithelial cells infected with the Omicron JN.1 variant. We observed a clear dose-dependent reduction in viral infection, achieving up to 91.9% inhibition at 3 μM while maintaining acceptable cell viability. In addition, Fisetin displayed a selectivity index superior to that of Lopinavir, the positive antiviral control used in this study. Altogether, our findings demonstrate that Fisetin possesses reproducible antiviral activity in a physiologically relevant human lung model and support its role as a natural scaffold for the rational development of polymerase-targeting antivirals against emerging SARS-CoV-2 variants. Full article
(This article belongs to the Special Issue New Strategies for Antimicrobial Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 1602 KB  
Review
Mechanisms Operating in the Use of Transition Metal Complexes to Combat Antimicrobial Resistance
by Shiming Wu, Meishu Wang, Ziyi Liu and Chen Fu
Microorganisms 2025, 13(7), 1570; https://doi.org/10.3390/microorganisms13071570 - 3 Jul 2025
Cited by 8 | Viewed by 1981
Abstract
The increasing diversity and escalating drug resistance of bacterial pathogens have significantly compromised the efficacy of conventional antimicrobial agents, creating formidable challenges in modern infection control. These developments underscore the critical need for innovative therapeutic strategies to address the persistent global health burden [...] Read more.
The increasing diversity and escalating drug resistance of bacterial pathogens have significantly compromised the efficacy of conventional antimicrobial agents, creating formidable challenges in modern infection control. These developments underscore the critical need for innovative therapeutic strategies to address the persistent global health burden posed by microbial resistance. While metal-based compounds have been extensively studied for their anticancer properties in clinical applications, their potential in antimicrobial contexts remains relatively underexplored. This review systematically elaborates on the structure-activity relationship of metal complexes, with a focus on the unique characteristics of metal drugs that differ from organic small molecules. These drugs can overcome drug resistance through various mechanisms (such as generation of reactive oxygen species and penetration of biological membranes). Understanding these mechanisms provides a crucial basis for guiding ligand design and the development of delivery systems. Full article
(This article belongs to the Special Issue New Strategies for Antimicrobial Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop